Drugs Containing Excipient (Inactive Ingredient) MAGNESIUM SULFATE HEPTAHYDRATE

Branded drugs containing MAGNESIUM SULFATE HEPTAHYDRATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Melinta Therapeutics LLC	MINOCIN	minocycline hydrochloride	70842-160	MAGNESIUM SULFATE HEPTAHYDRATE

Generic drugs containing MAGNESIUM SULFATE HEPTAHYDRATE excipient

Company	Ingredient	NDC	Excipient
Melinta Therapeutics LLC	minocycline hydrochloride	70842-160	MAGNESIUM SULFATE HEPTAHYDRATE

Last updated: August 12, 2026

Magnesium sulfate heptahydrate is a mature, low-margin pharmaceutical excipient and active pharmaceutical ingredient with limited patent protection. Its commercial outlook depends on sterile injectable demand, hospital supply contracts, obstetric care, electrolyte replacement, and production economics rather than innovation-led pricing. Public companies generally do not report revenue for this compound separately, so financial analysis must use end-market demand, supplier capacity, qualification barriers, and pricing drivers.

Magnesium Sulfate Heptahydrate Market Dynamics, Financial Trajectory, and Pharmaceutical Patent Landscape

What is magnesium sulfate heptahydrate used for in pharmaceuticals?

Magnesium sulfate heptahydrate, MgSO4·7H2O, is the hydrated magnesium salt commonly known as Epsom salt. In pharmaceutical manufacturing, it is used both as an active ingredient and as a formulation component, depending on the product.

Its principal pharmaceutical applications are:

Application	Role	Commercial relevance
Injectable electrolyte products	Active ingredient	High quality and sterility requirements
Obstetric injections	Active ingredient for prevention or treatment of eclampsia and severe preeclampsia	Stable hospital and public-health demand
Hypomagnesemia treatment	Active ingredient	Hospital and outpatient use
Oral laxatives	Active ingredient	Commodity-oriented demand
Oral and topical products	Excipient or functional ingredient	Lower-margin, broad supplier base
Pharmaceutical manufacturing	Processing or formulation component	Dependent on formulation-specific compatibility

Magnesium sulfate injection is recognized in major pharmaceutical markets as a medicinal product for magnesium replacement and obstetric indications. The World Health Organization includes magnesium sulfate among medicines used for hypertensive disorders of pregnancy, including eclampsia prevention and treatment.[1]

The commercial distinction between pharmaceutical excipient and active ingredient is important. Injectable magnesium sulfate is usually purchased under active pharmaceutical ingredient or finished-drug specifications. In tablets, powders, topical products, and other dosage forms, it may be treated as a functional ingredient or excipient. These channels have different pricing, regulatory, and qualification requirements.

How large is the magnesium sulfate heptahydrate pharmaceutical market?

No authoritative public dataset isolates global revenue for pharmaceutical-grade magnesium sulfate heptahydrate from broader magnesium sulfate, inorganic salts, agricultural products, industrial chemicals, and finished injectable medicines.

The market is best analyzed as a layered value chain:

1. Magnesium sulfate heptahydrate raw material.
2. Pharmaceutical-grade API or excipient.
3. Sterile injectable finished products.
4. Hospital, government, and distributor procurement.

The raw-material market is substantially larger than the pharmaceutical-excipient market because magnesium sulfate is also used in agriculture, animal health, water treatment, industrial processing, and consumer products. Conversely, the value of finished magnesium sulfate injections includes manufacturing, sterilization, packaging, regulatory compliance, distribution, and hospital margins. Those revenues should not be attributed to the excipient itself.

What drives demand for pharmaceutical magnesium sulfate?

Demand is relatively defensive and linked to healthcare utilization rather than discretionary pharmaceutical spending.

The main demand drivers are:

• Maternal-health programs requiring magnesium sulfate for eclampsia and preeclampsia.
• Hospital treatment of hypomagnesemia.
• Emergency and critical-care use.
• Oral laxative products.
• Public-sector tenders and national essential-medicine programs.
• Generic injectable manufacturing.
• Regional growth in hospital infrastructure.
• Stockpiling by hospitals and government purchasers after supply disruptions.

Demand growth is likely to remain moderate. The compound is established, inexpensive, and clinically familiar. It does not benefit from the type of rapid volume expansion associated with new biologics, specialty medicines, or patented delivery technologies.

What is the financial trajectory for magnesium sulfate heptahydrate?

The financial trajectory is best characterized as stable volume, limited pricing power, and periodic margin volatility.

Financial variable	Expected direction	Principal driver
Pharmaceutical-grade volume	Low-to-moderate growth	Hospital demand and essential-medicine programs
Unit pricing	Flat to moderately volatile	Energy, sulfuric acid, magnesium feedstock, freight
Gross margin	Stable for qualified suppliers; pressured for commodity suppliers	Quality systems and customer qualification
Working capital	Periodically elevated	Public tenders, inventory requirements, and supply security
Supplier concentration	Higher in sterile and validated grades than in bulk material	Regulatory qualification and manufacturing controls
Patent-related margin	Minimal	No meaningful composition exclusivity
Contract value	More stable than spot pricing	Long-term supply agreements and hospital tenders

Revenue growth for a supplier is more likely to come from geographic expansion, sterile-grade qualification, contract manufacturing, packaging, and supply reliability than from higher molecule-level pricing.

A producer selling industrial-grade magnesium sulfate faces commodity pricing. A producer supplying validated pharmaceutical-grade material can obtain a quality premium, but the premium is limited by the availability of alternative suppliers and the simplicity of the molecule.

Which cost factors affect magnesium sulfate heptahydrate margins?

The key cost inputs are:

• Magnesium-containing feedstock.
• Sulfuric acid or sulfate-processing inputs.
• Purified water.
• Crystallization and drying.
• Energy for evaporation and drying.
• Clean-room or controlled-environment processing.
• Microbiological testing.
• Heavy-metal and elemental-impurity testing.
• Packaging and moisture control.
• Freight, especially for low-value bulk shipments.

The heptahydrate form contains a high proportion of crystallization water. That reduces the value density of the product and makes freight, packaging, and moisture management material cost considerations. Producers close to raw-material sources or major pharmaceutical markets have a logistical advantage.

What regulatory standards apply to pharmaceutical-grade magnesium sulfate heptahydrate?

Pharmaceutical-grade material must comply with the applicable pharmacopoeial monograph and the customer’s approved specification. Relevant standards can include the United States Pharmacopeia-National Formulary, European Pharmacopoeia, British Pharmacopoeia, and Japanese Pharmacopoeia, depending on the destination market.[2]

Typical quality attributes include:

• Identity.
• Assay.
• Water content or hydration state.
• Appearance.
• Acidity or alkalinity.
• Chloride and other anionic impurities.
• Calcium and other elemental impurities.
• Heavy metals or elemental impurities under ICH Q3D.
• Insoluble matter.
• Microbial limits.
• Bacterial endotoxins for material used in parenteral manufacturing.
• Particle-size distribution where dosage-form performance requires control.

The heptahydrate state is a critical technical issue. Hydrated salts can lose or gain water during storage and processing. A supplier must control drying conditions, packaging, relative humidity, and testing methods to ensure that the material remains within the intended specification.

For injectable products, the finished dosage form must satisfy sterile manufacturing, container-closure, particulate, endotoxin, and stability requirements. Bulk pharmaceutical-grade material does not become an injectable product merely by meeting an assay specification.

What is the FDA regulatory status of magnesium sulfate products?

The FDA regulates magnesium sulfate products according to their dosage form, labeling, manufacturing process, and intended use. Magnesium sulfate injection is marketed as a prescription drug product, while certain oral products may be regulated under different pathways depending on labeling and formulation.

FDA-approved magnesium sulfate injection labeling identifies uses that include treatment of magnesium deficiency and obstetric management involving preeclampsia or eclampsia.[3] The finished drug product must comply with applicable current good manufacturing practice requirements under 21 C.F.R. Parts 210 and 211.[4]

The regulatory profile has several consequences for suppliers:

• A raw-material supplier may need a drug master file or equivalent confidential technical package.
• Finished-drug manufacturers must qualify the supplier and control changes.
• Sterile products face higher regulatory and operational barriers than oral products.
• A change in source, grade, hydration state, or manufacturing process can require regulatory assessment.
• Government purchasers may prioritize approved or prequalified finished products.

What is the Orange Book status of magnesium sulfate heptahydrate?

Magnesium sulfate heptahydrate as a raw material is not listed independently in the FDA Orange Book. The Orange Book lists approved drug products and associated patents or exclusivity information, not every excipient or API sold into pharmaceutical manufacturing.[5]

Finished magnesium sulfate drug products may appear in FDA databases according to product formulation, dosage form, route of administration, and applicant. Orange Book patent listings are generally relevant to the approved finished product, not to the underlying magnesium sulfate molecule.

Because magnesium sulfate is an old, simple inorganic compound, the commercial importance of Orange Book-listed patents is limited compared with patented small molecules and biologics.

What patents protect magnesium sulfate heptahydrate?

No meaningful composition-of-matter patent estate protects magnesium sulfate heptahydrate as a pharmaceutical compound. The molecule has been known and used for many years, placing it outside the practical scope of modern composition patents.

Potentially relevant intellectual property may instead concern:

• Injectable formulations.
• Premixed infusion bags.
• Concentration and dosing systems.
• Container-closure systems.
• Compatibility with other electrolytes.
• Stabilization or pH-control methods.
• Manufacturing processes.
• Combination products.
• Delivery devices.
• Packaging that controls hydration or contamination.

These rights, where they exist, would generally protect a particular product or process rather than magnesium sulfate heptahydrate itself.

How strong is the patent estate for magnesium sulfate heptahydrate?

The molecule-level patent estate is weak or effectively absent. The commercial protection profile is based on regulatory compliance, customer qualification, manufacturing controls, and supply reliability.

Protection category	Strength
Composition of matter	Very weak or unavailable
Core manufacturing process	Generally weak for a mature inorganic salt
Sterile injectable formulation	Product-specific and potentially moderate
Premixed infusion system	Potentially stronger if device or formulation claims apply
Method of use	Usually limited because the main uses are established
Trade secrets	Potentially relevant for process control and impurity management
Regulatory qualification	Strong practical barrier, especially for parenteral supply

Are there Paragraph IV challenges or generic-entry risks?

Paragraph IV litigation is unlikely to be material for the magnesium sulfate molecule itself. A generic applicant could challenge patents listed for a specific branded or proprietary finished product if those patents existed, but the underlying salt is broadly available.

Generic-entry risks are more operational than legal:

• A new supplier may fail customer qualification.
• Injectable manufacturers may face inspection or sterility deficiencies.
• A formulation change may create stability or compatibility problems.
• A low-price bidder may not maintain reliable supply.
• A supplier may lack validated documentation for regulated markets.
• Government tenders may favor approved suppliers with prior delivery records.

For finished injectable products, generic competition can be intense because the active ingredient is inexpensive and clinically established. However, sterile manufacturing capacity, regulatory compliance, and hospital procurement relationships can delay effective entry.

What formulation patents protect magnesium sulfate products?

Formulation patents may cover a specific concentration, solvent system, co-administered active ingredient, container, or administration method. The most commercially relevant potential claims involve:

• Ready-to-use premixed bags.
• Concentrated solutions requiring dilution.
• Compatibility with parenteral nutrition or other IV products.
• Reduced precipitation or degradation.
• Improved storage stability.
• Unit-dose packaging.
• Automated dosing systems.
• Combination electrolyte formulations.

These patents must be assessed at the finished-product level. They do not create broad exclusivity over pharmaceutical magnesium sulfate heptahydrate.

Which companies compete in the magnesium sulfate heptahydrate market?

Competition is fragmented across chemical manufacturers, API suppliers, generic injectable manufacturers, contract manufacturers, and hospital-product companies.

The relevant competitive groups include:

1. Bulk chemical producers supplying magnesium sulfate.
2. Pharmaceutical excipient distributors.
3. API manufacturers with pharmacopoeial-grade material.
4. Generic injectable manufacturers.
5. Hospital and public-sector suppliers.
6. Specialty manufacturers offering sterile or premixed presentations.

Competitive advantage depends on the product tier:

• Bulk material competes primarily on cost and logistics.
• Pharmaceutical-grade material competes on documentation, consistency, and qualification.
• Injectable products compete on regulatory status, fill-finish capacity, availability, and tender access.
• Premixed products compete on convenience, storage, and reduced preparation risk.

A supplier with only industrial-grade capacity cannot automatically compete in sterile pharmaceutical supply.

How does magnesium sulfate compare with alternative magnesium salts?

Magnesium salt	Relative pharmaceutical profile	Competitive position
Magnesium sulfate	Established injectable and oral uses; inexpensive	Strongest position in obstetric and hospital applications
Magnesium chloride	Injectable and oral uses in selected markets; different chloride burden	Alternative where chloride compatibility is acceptable
Magnesium gluconate	Mainly oral supplementation	Competes in consumer and outpatient products
Magnesium oxide	High elemental-magnesium content; poor solubility	Common oral alternative
Magnesium citrate	Oral laxative and supplementation use	Strong in oral consumer products
Magnesium lactate	Oral supplementation	More specialized

Substitution is limited by route, indication, dose, solubility, counter-ion effects, osmolality, and regulatory approval. Magnesium oxide or citrate may substitute in oral products, but they are not direct replacements for magnesium sulfate injection in obstetric or acute-care settings.

What geographic markets are most important?

The main geographic demand centers are:

• North America, due to hospital procurement and regulated generic supply.
• Europe, due to pharmacopoeial standards and centralized or national purchasing.
• China and India, due to API and finished-dose manufacturing capacity.
• Latin America, due to public-health procurement and hospital demand.
• Africa and parts of Asia, due to maternal-health programs and essential-medicine needs.

Local production can be strategically important where imported low-value material is exposed to freight costs, currency volatility, or supply interruptions. In lower-income markets, demand may be supported by international procurement programs and government tenders rather than private-pay pharmaceutical spending.

What manufacturing and intellectual-property barriers affect supply?

Manufacturing barriers are modest for bulk material but significant for validated pharmaceutical and sterile grades.

Bulk-grade barriers

• Access to suitable magnesium feedstock.
• Crystallization and drying capability.
• Impurity control.
• Consistent hydration state.
• Cost-effective packaging.
• Reliable export logistics.

Pharmaceutical-grade barriers

• Pharmacopoeial compliance.
• Validated analytical methods.
• Change-control systems.
• Audit readiness.
• Traceability.
• Stability data.
• Quality agreements with customers.

Sterile-product barriers

• Aseptic processing or terminal sterilization capability.
• Endotoxin control.
• Container-closure validation.
• Particulate control.
• Inspection compliance.
• Shortage-management and continuity planning.

These barriers create a practical moat around qualified supply despite the absence of strong patents.

What litigation and licensing issues affect magnesium sulfate?

There is no broad, molecule-level litigation pattern comparable with patented oncology drugs, insulin products, or biologics. Litigation risk is more likely to arise from:

• Supply contracts.
• Product-quality disputes.
• Batch failures.
• Regulatory noncompliance.
• Trademark or labeling claims.
• Device patents for premixed or automated delivery systems.
• Manufacturing agreements.
• Exclusivity arrangements with distributors or hospital systems.

Licensing transactions are also likely to involve finished-dose formulations, distribution rights, contract manufacturing, or regional tenders rather than rights to the magnesium sulfate molecule.

What generic launch scenarios exist for magnesium sulfate products?

A generic launch would face three distinct scenarios.

Bulk excipient launch

Entry can be relatively rapid if the supplier has compliant manufacturing, analytical data, and customer qualification. Price competition would be strong.

Oral dosage-form launch

Entry depends on formulation, labeling, and applicable regulatory pathway. The compound is inexpensive, so manufacturing scale and distribution are more important than API cost.

Injectable launch

Entry is slower because of sterile manufacturing, regulatory review, validation, and hospital procurement. A new entrant could still gain share if incumbent suppliers face shortages, quality actions, or capacity constraints.

The most credible commercial risk to an incumbent is therefore a qualified supplier with reliable sterile capacity, not a patent challenger.

Key Takeaways

• Magnesium sulfate heptahydrate is a mature pharmaceutical salt with no meaningful composition-of-matter exclusivity.
• Its market is divided between bulk chemical supply, pharmaceutical-grade API or excipient supply, and finished injectable products.
• Public companies generally do not report standalone revenue for the compound.
• Financial performance depends on volume, procurement contracts, quality premiums, energy costs, freight, and supply reliability.
• Injectable and sterile-grade supply has substantially higher barriers than oral or industrial material.
• FDA and Orange Book analysis applies primarily to finished magnesium sulfate drug products, not to the raw excipient.
• Paragraph IV litigation and biosimilar risk are not material to the molecule.
• Formulation, packaging, premixed-infusion, and delivery-system patents may create product-specific protection.
• Generic competition is strongest in bulk and oral products and more constrained in sterile injectables.
• The most durable commercial advantages are regulatory qualification, manufacturing consistency, documentation, and hospital or government procurement access.

FAQs

Is magnesium sulfate heptahydrate an API or an excipient?

It can be either. In injectable magnesium sulfate products and some oral medicines, it is the active ingredient. In other formulations, it can function as a pharmaceutical ingredient or excipient.

Does magnesium sulfate heptahydrate have biosimilar competition?

No. Biosimilar regulation applies to biological products. Magnesium sulfate heptahydrate is a small inorganic salt and is regulated through conventional drug, API, excipient, or chemical-product frameworks.

Can pharmaceutical-grade magnesium sulfate be replaced by industrial-grade material?

Not without qualification and regulatory assessment. Industrial-grade material may not meet pharmacopoeial, elemental-impurity, microbial, endotoxin, documentation, or traceability requirements.

Does the heptahydrate form affect pharmaceutical manufacturing?

Yes. Hydration state affects assay calculations, molecular weight, stability, water content, crystallization behavior, and formulation performance. Packaging and storage conditions must prevent uncontrolled dehydration or rehydration.

What is the main investment risk in magnesium sulfate heptahydrate?

The main risk is margin compression rather than patent loss. Low-value bulk pricing, supply oversupply, energy costs, freight, failed quality audits, and customer concentration are more important risks than intellectual-property expiration.

References

1. World Health Organization. (2023). WHO model list of essential medicines: 23rd list. Geneva, Switzerland: World Health Organization.

2. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. Rockville, MD: United States Pharmacopeial Convention.

3. U.S. Food and Drug Administration. (n.d.). Magnesium sulfate injection prescribing information. Silver Spring, MD: U.S. Food and Drug Administration.

4. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. Silver Spring, MD: U.S. Food and Drug Administration.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Silver Spring, MD: U.S. Food and Drug Administration.